LeonaBio, Inc.
corporate_fare Company Profile
LeonaBio, Inc. (NASDAQ:LONA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for LONA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for LONA spans 10-Q, 8-K, SCHEDULE 13D, DEF 14A.
Recent high-impact activity:
- LeonaBio Q3 Cash Falls to $32.3M; Going Concern Warning Reiterated
- Cash Falls to $32.3M as Q3 Net Loss Widens to $21.2M; ELAINE-3 Enrollment Slips to 4Q 2026
- LeonaBio's 23M Series A Warrants Now Exercisable, Potential $146.2M Cash Inflow
- Sermonix Exercises 3.15M Warrants, Distributes 4.73M LeonaBio Shares
- LeonaBio Reaches 500th Patient in Phase 3 ELAINE-3, Opening $146M Warrant Exercise Window
Financial Snapshot
Short Interest & Short Volume
1.13 days to coverFINRA reported short interest of 74,491 shares in LONA as of the October 30, 2026 settlement, a 14.7% decrease from the prior period — about 1.1 days to cover at its recent average daily volume. On November 20, 2026, 43.1% of LONA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.